Juraschek Stephen P, Hu Jiun-Ruey, Cluett Jennifer L, Mita Carol, Lipsitz Lewis A, Appel Lawrence J, Beckett Nigel S, Davis Barry R, Holman Rury R, Miller Edgar R, Mukamal Kenneth J, Peters Ruth, Staessen Jan A, Taylor Addison A, Wright Jackson T, Cushman William C
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
BMJ. 2025 Mar 25;388:e080507. doi: 10.1136/bmj-2024-080507.
To determine the effects of intensive blood pressure treatment on orthostatic hypertension.
Systematic review and individual participant data meta-analysis.
MEDLINE, Embase, and Cochrane CENTRAL databases through 13 November 2023.
Population: ≥500 adults, age ≥18 years with hypertension or elevated blood pressure; intervention: randomized trials of more intensive antihypertensive drug treatment (lower blood pressure goal or active agent) with duration ≥6 months; control: less intensive antihypertensive drug treatment (higher blood pressure goal or placebo); outcome: measured standing blood pressure.
Orthostatic hypertension, defined as an increase in systolic blood pressure ≥20 mm Hg or diastolic blood pressure ≥10 mm Hg after changing from sitting to standing.
Two investigators independently abstracted articles. Individual participant data from nine trials identified during the systematic review were appended together as a single dataset.
Of 31 124 participants with 315 497 standing blood pressure assessments, 9% had orthostatic hypotension (that is, a drop in blood pressure after standing of systolic ≥20 mm Hg or diastolic ≥10 mm Hg), 17% had orthostatic hypertension, and 3.2% had both a rise in systolic blood pressure and standing blood pressure ≥140 mm Hg at baseline. The effects of more intensive treatment were similar across trials with odds ratios for orthostatic hypertension ranging from 0.85 to 1.08 (I=38.0%). During follow-up, 17% of patients assigned to more intensive treatment had orthostatic hypertension, whereas 19% of those assigned less intensive treatment had orthostatic hypertension. Compared with less intensive treatment, the risk of orthostatic hypertension was lower with more intensive blood pressure treatment (odds ratio 0.93, 95% confidence interval 0.90 to 0.96). Effects were greater among non-black versus black adults (odds ratio 0.86 0.97; P for interaction=0.003) and adults without diabetes versus those with diabetes (0.88 0.96; P for interaction=0.05) but did not differ by age ≥75 years, sex, baseline seated blood pressure ≥130/≥80 mm Hg, obesity, stage 3 kidney disease, stroke, cardiovascular disease, standing systolic blood pressure ≥140 mm Hg, or pre-randomization orthostatic hypertension (P for interactions ≥0.05).
In this pooled cohort of adults with elevated blood pressure or hypertension, orthostatic hypertension was common and more intensive blood pressure treatment modestly reduced the occurrence of orthostatic hypertension. These findings suggest that approaches generally used for seated hypertension may also prevent hypertension on standing.
Prospero CRD42020153753 (original proposal).
确定强化血压治疗对体位性高血压的影响。
系统评价和个体参与者数据荟萃分析。
截至2023年11月13日的MEDLINE、Embase和Cochrane CENTRAL数据库。
人群:≥500名成年人,年龄≥18岁,患有高血压或血压升高;干预:持续时间≥6个月的强化抗高血压药物治疗(更低血压目标或活性药物)的随机试验;对照:不太强化的抗高血压药物治疗(更高血压目标或安慰剂);结局:测量站立位血压。
体位性高血压,定义为从坐位变为站立位后收缩压升高≥20 mmHg或舒张压升高≥10 mmHg。
两名研究者独立提取文章信息。在系统评价过程中确定的9项试验的个体参与者数据被合并为一个数据集。
在31124名参与者的315497次站立位血压评估中,9%有体位性低血压(即站立后收缩压下降≥20 mmHg或舒张压下降≥10 mmHg),17%有体位性高血压,3.2%在基线时收缩压和站立位血压均升高且≥140 mmHg。各试验中强化治疗的效果相似,体位性高血压的比值比在0.85至1.08之间(I=38.0%)。在随访期间,分配接受强化治疗的患者中有17%患有体位性高血压,而分配接受不太强化治疗的患者中有19%患有体位性高血压。与不太强化的治疗相比,强化血压治疗使体位性高血压的风险更低(比值比0.93,95%置信区间0.90至0.96)。非黑人成年人与黑人成年人相比(比值比0.86对0.97;交互作用P=0.003)以及无糖尿病成年人与有糖尿病成年人相比(0.88对0.96;交互作用P=0.05)效果更明显,但在年龄≥75岁、性别、基线坐位血压≥130/≥80 mmHg、肥胖、3期肾病、中风、心血管疾病、站立位收缩压≥140 mmHg或随机分组前体位性高血压方面无差异(交互作用P≥0.05)。
在这个血压升高或患有高血压的成年人汇总队列中,体位性高血压很常见,强化血压治疗适度降低了体位性高血压的发生率。这些发现表明,通常用于坐位高血压的方法也可能预防站立时的高血压。
Prospero CRD42020153753(原始提案)